Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... [Yahoo! Finance]
Lantern Pharma Inc. (LTRN)
Company Research
Source: Yahoo! Finance
R&D Expenses: Approximately $3.7 million for Q3 2024, up from $2.2 million for Q3 2023. General and Administrative Expenses: Approximately $1.5 million for Q3 2024, up from $1.3 million for Q3 2023. Interest and Other Income: Approximately $674,000 for Q3 2024, compared to $362,000 for Q3 2023. Cash Position: Approximately $28.1 million as of September 30, 2024. Shares Outstanding: 10,784,725 shares of common stock as of September 30, 2024. Fully Diluted Shares Outstanding: Approximately 12.1 million shares as of September 30, 2024. Warning! GuruFocus has detected 1 Warning Sign with LTRN. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Lantern Pharma Inc ( NASDAQ:LTRN ) has made significant clinical progress with its AI-guided drug programs, including the ongoing Phase 2 HARMONIC trial and Phase 1 programs for LP-184 and LP-284. The company received FDA Fast Track designation for
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsBusiness Wire
- Lantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesBusiness Wire
- Starlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardBusiness Wire
- Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETBusiness Wire
LTRN
Earnings
- 11/7/24 - Beat
LTRN
Sec Filings
- 11/8/24 - Form 8-K
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- LTRN's page on the SEC website